Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Lung Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Breast Neoplasms 6Head and Neck Neoplasms 4Uterine Cervical Neoplasms 3Tobacco Use Disorder 3Small Cell Lung Carcinoma 3cyclopia sequence 2Urinary Bladder Neoplasms 2Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Smoking Cessation 2Pancreatic Neoplasms 2Overweight 2Ovarian Neoplasms 2Oropharyngeal Neoplasms 2Obesity 2Nasopharyngeal Neoplasms 2Mouth Neoplasms 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Leukemia 2Laryngeal Neoplasms 2Kidney Neoplasms 2Hypopharyngeal Neoplasms 2Esophageal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Hepatocellular 2Advanced Solid Tumor 2Vulvar Neoplasms 1

Interventions

vorasidenib 1repaglinide 1Rosuvastatin Calcium 1Omeprazole 1Midazolam 1Flurbiprofen 1Bupropion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Healthy Adult Participants × Bupropion × Clear all
NCT07235748 2026-02-17

Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

Servier

Phase 1 Completed
28 enrolled

Healthy Adult Participants

Data powered by HemOnc (CC BY 4.0) Colophon âš¡